PROLOR Biotech to Present at Lazard Capital Markets 8th Annual Healthcare Conference

NES-ZIONA, Israel, Nov. 8, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Lazard Capital Markets 8th Annual Healthcare Conference at 9:00 AM EST on November 15, 2011.  The conference will be held at the Pierre Hotel in New York City.

For more information about the Lazard 8th Annual Healthcare Conference, visit www.lazardcap.com/conferenceList.aspx?tn=4&ln=3&itm=3579&lid=1901

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, as well as agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development.  For more information, visit www.prolor-biotech.com.

SOURCE PROLOR Biotech, Inc.